Scholarlink

Purpose of Review <p>Edaravone Dexborneol, a novel neuroprotective agent that combines antioxidant and anti-inflammatory properties,&#xa0;has emerged as a promising treatment for acute ischemic stroke (AIS). This systematic review evaluates its&#xa0;effectiveness and safety compared to Edaravone alone, placebo, alteplase, or no treatment.</p> Recent Findings <p>Six studies (four randomized controlled trials, one retrospective, and one observational) involving 2,814 AIS patients&#xa0;treated within 48 hours were reviewed. Functional outcomes (modified Rankin Scale [mRS] ≤1 or 2 at 90 days),&#xa0;neurological improvement (NIHSS), and biomarker changes (e.g., cytokines) were assessed. Meta-analysis of four&#xa0;studies (<i>n </i>= 2,306) showed a pooled odds ratio of 1.59, indicating a 59% greater likelihood of favorable outcomes&#xa0;with Edaravone Dexborneol. Two large Phase III trials (TASTE and TASTE-SL) reported significant benefits (OR 1.42,&#xa0;<i>p </i>= 0.004; OR 1.50, <i>p </i>= 0.003) with low risk of bias. Three studies demonstrated improved NIHSS scores and&#xa0;reductions in proinflammatory markers such as IL-6. Safety outcomes were comparable to controls, with one study&#xa0;showing significantly lower rates of hemorrhagic transformation in large vessel occlusion patients (20.29% vs.&#xa0;39.73%, <i>p </i>= 0.0006).</p> Summary <p>Edaravone Dexborneol significantly improves functional recovery in AIS and appears safe based on current evidence.&#xa0;While high-quality data support its use, the predominance of Chinese cohorts and study heterogeneity highlight the&#xa0;need for multi-ethnic RCTs and long-term follow-up to ensure broader applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness and Safety of Edavarone and Dexborneol in Acute Ischemic Stroke: A Systematic Review

  • 期刊论文

  • 发表日期：

    2025年6月13日

查看全文
  • Nicholas Aderinto,
  • Ismaila Ajayi Yusuf,
  • Gbolahan Olatunji,
  • Emmanuel Kokori,
  • Adetola Emmanuel,
  • Olaewe David Opeyemi,
  • Adefusi Temiloluwa Oluwakorede,
  • Stephen Oludu,
  • Elijah Akinbi,
  • Oluwatobi Taiwo Omoworare

摘要

Purpose of Review

Edaravone Dexborneol, a novel neuroprotective agent that combines antioxidant and anti-inflammatory properties, has emerged as a promising treatment for acute ischemic stroke (AIS). This systematic review evaluates its effectiveness and safety compared to Edaravone alone, placebo, alteplase, or no treatment.

Recent Findings

Six studies (four randomized controlled trials, one retrospective, and one observational) involving 2,814 AIS patients treated within 48 hours were reviewed. Functional outcomes (modified Rankin Scale [mRS] ≤1 or 2 at 90 days), neurological improvement (NIHSS), and biomarker changes (e.g., cytokines) were assessed. Meta-analysis of four studies (n = 2,306) showed a pooled odds ratio of 1.59, indicating a 59% greater likelihood of favorable outcomes with Edaravone Dexborneol. Two large Phase III trials (TASTE and TASTE-SL) reported significant benefits (OR 1.42, p = 0.004; OR 1.50, p = 0.003) with low risk of bias. Three studies demonstrated improved NIHSS scores and reductions in proinflammatory markers such as IL-6. Safety outcomes were comparable to controls, with one study showing significantly lower rates of hemorrhagic transformation in large vessel occlusion patients (20.29% vs. 39.73%, p = 0.0006).

Summary

Edaravone Dexborneol significantly improves functional recovery in AIS and appears safe based on current evidence. While high-quality data support its use, the predominance of Chinese cohorts and study heterogeneity highlight the need for multi-ethnic RCTs and long-term follow-up to ensure broader applicability.